Novel Glioblastoma Therapeutics

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$109,860.00
Award Year:
2007
Program:
STTR
Phase:
Phase I
Contract:
1R41CA126020-01
Agency Tracking Number:
CA126020
Solicitation Year:
2007
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
TERPENOID THERAPEUTICS, INC.
2501 Crosspark Road, Room B126-MTF, Coralville, IA, 52241
Hubzone Owned:
N
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
602743903
Principal Investigator:
JEFFREY NEIGHBORS
(319) 335-1467
JEFFREY-NEIGHBORS@UIOWA.EDU
Business Contact:
(319) 335-1467
jeffrey-neighbors@uiowa.edu
Research Institution:
UNIVERSITY OF IOWA

UNIVERSITY OF IOWA
IOWA CITY, IA, 52242-3364

Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): The overall goal of the proposed studies is to establish the feasibility of developing therapies for brain cancers such as glioblastoma multiforme from the schweinfurthin family of antiproliferative agents. These agents are highly toxic to CNS derived tumor cell lines in vitro and more importantly appear to exhibit this activity via a novel cellular target(s). The schweinfurthins also contain chemical functional groups which should facilitate cerebrovascular barrier penetration, a very important aspect of drugs aimed at treating primary brain cancers. Phase One of these studies is comprised of three narrowly focused aims directed at proving the feasibility of finding advancing? a therapeutic lead from this family: These aims include: 1) synthesis of analogs of the schweinfurthins bearing functional groups designed to improve the "drug-like" nature of the compounds; 2) improvement of the published synthesis of the hexahydroxanthene core of the 3-deoxyschweinfurthin motif to allow for more efficient and safe production of larger quantities of material for Phase Two studies; and 3) biological studies aimed at elucidation of the cellular or molecular target of the schweinfurthins. These aims will allow a decision to be made about feasibility of studying these drugs further in pre-clinical animal models as part of Phase Two, and ultimately of bringing drugs based on this unique and potent family of compounds into use against brain cancer.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government